Exact Mass: 717.3489

Exact Mass Matches: 717.3489

Found 39 metabolites which its exact mass value is equals to given mass value 717.3489, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

N-[3-[5,8-bis[3-[acetyl(hydroxy)amino]propyl]-14-(hydroxymethyl)-3,6,9,12,15,18-hexaoxo-1,4,7,10,13,16-hexazacyclooctadec-2-yl]propyl]-N-hydroxyacetamide

NCGC00347686-02!N-[3-[5,8-bis[3-[acetyl(hydroxy)amino]propyl]-14-(hydroxymethyl)-3,6,9,12,15,18-hexaoxo-1,4,7,10,13,16-hexazacyclooctadec-2-yl]propyl]-N-hydroxyacetamide

C28H47N9O13 (717.3293)

Ferricrocin [M-H2+Fe]

C28H47N9O13 (717.3293)

N-[3-[5,8-bis[3-[acetyl(hydroxy)amino]propyl]-14-(hydroxymethyl)-3,6,9,12,15,18-hexaoxo-1,4,7,10,13,16-hexazacyclooctadec-2-yl]propyl]-N-hydroxyacetamide [IIN-based: Match]

NCGC00347686-02!N-[3-[5,8-bis[3-[acetyl(hydroxy)amino]propyl]-14-(hydroxymethyl)-3,6,9,12,15,18-hexaoxo-1,4,7,10,13,16-hexazacyclooctadec-2-yl]propyl]-N-hydroxyacetamide [IIN-based: Match]

C28H47N9O13 (717.3293)

FYLLY

Phe-Tyr-Leu-Leu-Tyr

C39H51N5O8 (717.3737)

NYQFF

Asn-Tyr-Gln-Phe-Phe

C36H43N7O9 (717.3122)

ho(tmhd)3

C33H60HoO6 (717.3693)

Desferri-ferricrocin

C28H47N9O13 (717.3293)

D000890 - Anti-Infective Agents > D023181 - Antimicrobial Cationic Peptides

[(1S,4R,6S,7E,14S,18R)-4-[(cyclopropylsulfonylamino)methyl]-14-[(2-methylpropan-2-yl)oxycarbonylamino]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-18-yl] 4-fluoro-1,3-dihydroisoindole-2-carboxylate

[(1S,4R,6S,7E,14S,18R)-4-[(cyclopropylsulfonylamino)methyl]-14-[(2-methylpropan-2-yl)oxycarbonylamino]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-18-yl] 4-fluoro-1,3-dihydroisoindole-2-carboxylate

C35H48FN5O8S (717.3207)

Methyl 7-[[5-[[2-(2-hydroxyphenyl)-4,5-dihydro-1,3-oxazole-4-carbonyl]amino]-6-[4-[(1-oxido-2-oxoazepan-3-yl)amino]-4-oxobutan-2-yl]oxy-6-oxohexyl]-oxidoamino]-7-oxoheptanoate

C34H47N5O12-2 (717.3221)

14-(Hydroxymethyl)-2,5,8-tris[3-[(acetyl)(hydroxy)amino]propyl]-1,4,7,10,13,16-hexaazacyclooctadecane-3,6,9,12,15,18-hexaone

C28H47N9O13 (717.3293)

N-[1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxydecan-2-yl]acetamide

C30H55NO18 (717.3419)

N-[1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxynonan-2-yl]propanamide

C30H55NO18 (717.3419)

N-[1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoctan-2-yl]butanamide

C30H55NO18 (717.3419)

(2S)-2-amino-3-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C38H56NO10P (717.3642)

(2S)-2-amino-3-[[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C38H56NO10P (717.3642)

LNAPS 32:9

C38H56NO10P (717.3642)

PS O-29:5;O3

C35H60NO12P (717.3853)

PS P-18:1/11:3;O3

C35H60NO12P (717.3853)

PS 16:0/13:4;O2

C35H60NO12P (717.3853)

PS 16:1/13:3;O2

C35H60NO12P (717.3853)

PS 20:0/9:4;O2

C35H60NO12P (717.3853)

PS 20:2/8:3;O3

C34H56NO13P (717.3489)

PS 20:3/8:2;O3

C34H56NO13P (717.3489)

PS 20:3/9:1;O2

C35H60NO12P (717.3853)

PS 22:1/7:3;O2

C35H60NO12P (717.3853)

PS 22:2/7:2;O2

C35H60NO12P (717.3853)

PS 28:5;O3

C34H56NO13P (717.3489)

PS 29:4;O2

C35H60NO12P (717.3853)

Hex3Cer 12:0;O2

C30H55NO18 (717.3419)

SHexCer 29:5;O3

C35H59NO12S (717.3758)

ST 29:7;O8;HexNAc

C37H51NO13 (717.336)

Cyclo(-RGDfK) (TFA)

C29H42F3N9O9 (717.3057)

Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM[1]. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface[3].

(2s,3r,4e,6r)-6-[(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,5-trihydroxy-9a,11a-dimethyl-7-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthren-1-yl]-2,3-dimethyl-n-(2-sulfoethyl)hept-4-enimidic acid

(2s,3r,4e,6r)-6-[(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,5-trihydroxy-9a,11a-dimethyl-7-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthren-1-yl]-2,3-dimethyl-n-(2-sulfoethyl)hept-4-enimidic acid

C35H59NO12S (717.3758)

n-(3-{3,6,9,12,15,18-hexahydroxy-14,17-bis[3-(n-hydroxyacetamido)propyl]-8-(hydroxymethyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl}propyl)-n-hydroxyacetamide

C28H47N9O13 (717.3293)

(2s,3r,4e,6s)-6-[(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,5-trihydroxy-9a,11a-dimethyl-7-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthren-1-yl]-2,3-dimethyl-n-(2-sulfoethyl)hept-4-enimidic acid

(2s,3r,4e,6s)-6-[(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,5-trihydroxy-9a,11a-dimethyl-7-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthren-1-yl]-2,3-dimethyl-n-(2-sulfoethyl)hept-4-enimidic acid

C35H59NO12S (717.3758)

2-[(2-{[2-({2-[(3-amino-10,10-dichloro-1,2-dihydroxydecylidene)amino]-1-hydroxypropylidene}amino)-1-hydroxy-3-methylbutylidene]amino}-1-hydroxy-4-methylpentylidene)amino]-3-(4-hydroxyphenyl)propanoic acid

2-[(2-{[2-({2-[(3-amino-10,10-dichloro-1,2-dihydroxydecylidene)amino]-1-hydroxypropylidene}amino)-1-hydroxy-3-methylbutylidene]amino}-1-hydroxy-4-methylpentylidene)amino]-3-(4-hydroxyphenyl)propanoic acid

C33H53Cl2N5O8 (717.3271)